Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT01015833 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01015833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01015833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Completed
Start date
February 15, 2010
Completion date
August 15, 2018
Enrollment
356 (actual)
Sites
673

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adult hepatocellular carcinoma, recurrent hepatocellular carcinoma, stage iii hepatocellular carcinoma ajcc v7, stage iiia hepatocellular carcinoma ajcc v7, stage iiib hepatocellular carcinoma ajcc v7, stage iiic hepatocellular carcinoma ajcc v7, stage iv hepatocellular carcinoma ajcc v7, stage iva hepatocellular carcinoma ajcc v7, stage ivb hepatocellular carcinoma ajcc v7, unresectable hepatocellular carcinoma